Skip to content
10-Q

Quarterly Report

AMAG PHARMACEUTICALS, INC.

0000792977-20-000094

← back to feed
Filed
Nov 6, 2020 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Nov 4, 2020 34.73M sh
Shares Diluted Q3 2020 · Sep 30, 2020 34.72M sh
Shares Diluted Q3 2020 · Sep 30, 2020 34.31M sh
Shares Diluted Q3 2020 · Sep 30, 2019 33.91M sh
Shares Diluted Q3 2020 · Sep 30, 2019 34.06M sh
Stock Repurchased Q3 2020 · Sep 30, 2020 $0
Stock Repurchased Q3 2020 · Sep 30, 2019 $13.73M
Capex Q3 2020 · Sep 30, 2020 $475K
Capex Q3 2020 · Sep 30, 2019 $2.1M
Operating Cash Flow Q3 2020 · Sep 30, 2020 −$6.76M
Operating Cash Flow Q3 2020 · Sep 30, 2019 −$105.73M
Long Term Debt Q3 2020 · Sep 30, 2020 $289.33M
Long Term Debt Q3 2020 · Dec 31, 2019 $277.03M
Short Term Debt Q3 2020 · Sep 30, 2020 $0
Short Term Debt Q3 2020 · Dec 31, 2019 $0
Cash And Equivalents Q3 2020 · Sep 30, 2020 $97.98M
Cash And Equivalents Q3 2020 · Dec 31, 2019 $113.01M
Stockholders Equity Q3 2020 · Sep 30, 2020 $256.02M
Stockholders Equity Q3 2020 · Jun 30, 2020 $244.11M
Stockholders Equity Q3 2020 · Dec 31, 2019 $279.82M
Stockholders Equity restated Q3 2020 · Sep 30, 2019 $474.55M
Stockholders Equity restated Q3 2020 · Jun 30, 2019 $493.75M
Stockholders Equity restated Q3 2020 · Dec 31, 2018 $741.56M
Current Liabilities Q3 2020 · Sep 30, 2020 $161.98M
Current Liabilities Q3 2020 · Dec 31, 2019 $214.5M
Total Liabilities Q3 2020 · Sep 30, 2020 $478.33M
Total Liabilities Q3 2020 · Dec 31, 2019 $511.41M
Current Assets Q3 2020 · Sep 30, 2020 $283.37M
Current Assets Q3 2020 · Dec 31, 2019 $316.57M
Total Assets Q3 2020 · Sep 30, 2020 $734.36M
Total Assets Q3 2020 · Dec 31, 2019 $791.23M
Eps Diluted Q3 2020 · Sep 30, 2020 $0.28
Eps Diluted Q3 2020 · Sep 30, 2020 −$0.92
Eps Diluted Q3 2020 · Sep 30, 2019 −$0.71
Eps Diluted Q3 2020 · Sep 30, 2019 −$7.85
Eps Basic Q3 2020 · Sep 30, 2020 $0.28
Eps Basic Q3 2020 · Sep 30, 2020 −$0.92
Eps Basic Q3 2020 · Sep 30, 2019 −$0.71
Eps Basic Q3 2020 · Sep 30, 2019 −$7.85
Sga Expense Q3 2020 · Sep 30, 2020 $35.66M
Sga Expense Q3 2020 · Sep 30, 2020 $127.92M
Sga Expense Q3 2020 · Sep 30, 2019 $65.72M
Sga Expense Q3 2020 · Sep 30, 2019 $217.73M
Net Income Q3 2020 · Sep 30, 2020 $9.7M
Net Income Q3 2020 · Sep 30, 2020 −$31.47M
Net Income restated Q3 2020 · Sep 30, 2019 −$23.94M
Net Income restated Q3 2020 · Sep 30, 2019 −$267.51M
Operating Income Q3 2020 · Sep 30, 2020 $1.6M
Operating Income Q3 2020 · Sep 30, 2020 −$28.42M
Operating Income restated Q3 2020 · Sep 30, 2019 −$18.35M
Operating Income restated Q3 2020 · Sep 30, 2019 −$252.55M
Cost Of Revenue Q3 2020 · Sep 30, 2020 $13.34M
Cost Of Revenue Q3 2020 · Sep 30, 2020 $55.43M
Cost Of Revenue Q3 2020 · Sep 30, 2019 $21.11M
Cost Of Revenue Q3 2020 · Sep 30, 2019 $63.87M
Revenue Q3 2020 · Sep 30, 2020 $93.11M
Revenue Q3 2020 · Sep 30, 2020 $210.64M
Revenue restated Q3 2020 · Sep 30, 2019 $83.81M
Revenue restated Q3 2020 · Sep 30, 2019 $237.06M